Anthony Walker, PhD

Recent Posts

Disease Indication Strategy for Anti-Fibrotic Drugs

Introduction: Anti-fibrotic drug candidates, prior to entering clinical development, often have a mechanism of action that may be beneficial for treatment of multiple diseases. Early strategic issues...
Learn More

Obesity: Beyond Getting Slim Quick & GLP-1s

Looking Beyond GLP-1s Currently, much of the pharmaceutical industry and up to a quarter of the population of the developed world are captivated by get-slim-quick drugs known as GLP-1 agonists, and...
Learn More

The financing dose-response curve: how much is too much?

For biotechs, how much is too much? We’re all too aware of the rate of biotech company failures at the moment. This includes venture-backed companies that have raised well in excess of $100m,...
Learn More

What’s Bugging You? The Next Chapter for Microbiome Drugs

Depending on your perspective, live biotherapeutic products (LBPs) are either a promising, newly emergent class of therapeutic agents that utilize live microorganisms to prevent or treat various...
Learn More

Is it ever too early to consider new drug pricing strategy?

Is it ever too early to consider new drug pricing strategy?
Learn More

Cancer Vaccines: Ready for Prime Time or Another False Dawn?

Cancer Vaccines: Ready for Prime Time or Another False Dawn? Moderna and BioNTech recently reported positive early clinical data for mRNA cancer vaccines in combination with PD-1/L1 inhibitors, so...
Learn More

Drug Repurposing: Realities and Roadblocks

Drug Repurposing Market: Realities and Roadblocks We receive a steady stream of enquiries about opportunities in drug repurposing, often from people who see a short, low risk pathway to large...
Learn More

Adapting to Our “New” Virtual Reality in Biotech

In the current crisis, working virtually is now a reality for many. The preparedness for this varies greatly. For some it’s business as usual, for others “going virtual” simply hasn’t been feasible,...
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.